T
wo large-scale studies are being launched, to compare the effects on bone mineral density of two osteoporosis drugs. The alendronate and risedronate are known for their preventive action against the disease.However, their comparative effectiveness when used for curative purposes has not yet been assessed. One of these studies called FACT will be confined to U.S. territory.
The other, largely internationalized, our clinical research will be widely represented since 9 French teams will participate, providing one of the strongest contingents of patients.
Each will bring together 800 postmenopausal women suffering from osteoporosis proved. Each patient will receive once a week and 1 year, one or other of the two drugs. The results obtained with these two approaches will be compared and the first results should be published in two years.
Already today, one in three women between 60 and 70 years is suffering from osteoporosis. And if the disease causes a fracture every 30 seconds in Europe, it continues to grow and the majority of women is neither osteoporosis diagnosed nor treated….
For Professor Yves Maugars CHU de Nantes, for example, "it is now estimated that fewer than one in 10 with a fracture related to osteoporosis treats his illness! "
